Victor Sandor
Director/Board Member en MERUS N.V. .
Fortuna: 261 969 $ al 31/03/2024
Cargos activos de Victor Sandor
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
MERUS N.V. | Director/Board Member | 12/06/2019 | - |
Independent Dir/Board Member | 12/06/2019 | - | |
ADC THERAPEUTICS SA | Director/Board Member | 27/04/2020 | - |
Independent Dir/Board Member | 27/04/2020 | - | |
PRELUDE THERAPEUTICS INCORPORATED | Director/Board Member | 01/05/2020 | - |
Independent Dir/Board Member | - | - | |
KYMERA THERAPEUTICS, INC. | Director/Board Member | 03/11/2022 | - |
Independent Dir/Board Member | 03/11/2022 | - | |
Istari Oncology, Inc.
Istari Oncology, Inc. BiotechnologyHealth Technology Istari Oncology, Inc. operates as a clinical-stage biotechnology company. It focuses on novel immuno-oncology and immunotherapy platforms for the treatment of glioblastoma and a wide variety of tumors. Its core technology assets are PVS-RIPO, a prototypic oncolytic recombinant polio virus vaccine, and a series of antibody-drug conjugates comprising antibodies or antibody fragments to a variety of oncology targets. The company was founded by Darell D. Bigner and Matthias Gromeier in 2016 and is headquartered in Research Triangle Park, NC. | Director/Board Member | 01/07/2019 | - |
Historial de carrera de Victor Sandor
Antiguos cargos conocidos de Victor Sandor.
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
INCYTE CORPORATION | Chief Tech/Sci/R&D Officer | 01/01/2010 | 01/09/2019 |
ARRAY TECHNOLOGIES, INC. | Chief Tech/Sci/R&D Officer | 22/09/2014 | 01/08/2019 |
Biogen Idec, Inc. (North Carolina)
Biogen Idec, Inc. (North Carolina) Pharmaceuticals: MajorHealth Technology Part of Biogen, Inc., Biogen Idec, Inc. (North Carolina) is a pharmaceutical company based in Durham, NC. The private company develops pharmaceutical products. Michel Pericles Vounatsos has been the CEO of the company since 2016. | Corporate Officer/Principal | 01/02/2010 | 01/09/2014 |
Formación de Victor Sandor.
McGill University | Doctorate Degree |
Estadísticas
Internacional
Estados Unidos | 7 |
Canadá | 2 |
Países Bajos | 2 |
Operativa
Director/Board Member | 5 |
Independent Dir/Board Member | 4 |
Chief Tech/Sci/R&D Officer | 2 |
Sectorial
Health Technology | 9 |
Consumer Services | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas cotizadas | 5 |
---|---|
INCYTE CORPORATION | Health Technology |
MERUS N.V. | Health Technology |
ADC THERAPEUTICS SA | Health Technology |
PRELUDE THERAPEUTICS INCORPORATED | Health Technology |
KYMERA THERAPEUTICS, INC. | Health Technology |
Empresas privadas | 3 |
---|---|
Array BioPharma, Inc.
Array BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Array BioPharma, Inc. is a biopharmaceutical company. Its focus is on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer and other high-burden diseases. The company's products are BRAFTOVI and MEKTOVI. Its portfolio includes Binimetinib, Selumetinib, Encorafenib, Filanesib, Ipatasertib, Varltinib, Danoprevir, ARRY-797, Larotrectinib, Tucatinib, ARRY-382, Motolimod, Prexasertib, GDC-0575, LOXO-292, LOXO-195, and AK-1830. The company was founded by Kevin Koch, Anthony D. Piscopio, K. C. Nicolaou, and David L. Snitman in 1998 and is headquartered in Boulder, CO. | Health Technology |
Biogen Idec, Inc. (North Carolina)
Biogen Idec, Inc. (North Carolina) Pharmaceuticals: MajorHealth Technology Part of Biogen, Inc., Biogen Idec, Inc. (North Carolina) is a pharmaceutical company based in Durham, NC. The private company develops pharmaceutical products. Michel Pericles Vounatsos has been the CEO of the company since 2016. | Health Technology |
Istari Oncology, Inc.
Istari Oncology, Inc. BiotechnologyHealth Technology Istari Oncology, Inc. operates as a clinical-stage biotechnology company. It focuses on novel immuno-oncology and immunotherapy platforms for the treatment of glioblastoma and a wide variety of tumors. Its core technology assets are PVS-RIPO, a prototypic oncolytic recombinant polio virus vaccine, and a series of antibody-drug conjugates comprising antibodies or antibody fragments to a variety of oncology targets. The company was founded by Darell D. Bigner and Matthias Gromeier in 2016 and is headquartered in Research Triangle Park, NC. | Health Technology |
- Bolsa de valores
- Insiders
- Victor Sandor
- Experiencia